CLINICAL TRIALS PROFILE FOR NEOSAR

505(b)(2) Clinical Trials for NEOSAR

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Dosage	NCT01760226 ↗	Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies	Completed	National Cancer Institute (NCI)	Early Phase 1	2013-01-01	The subject is invited to take part in this research study because s/he has been diagnosed with Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal B-cell Lymphoma (PMBCL), or Post-transplant Lymphoproliferative Disorder (PTLD). In an attempt to improve cure rates while reducing harmful effects from drugs, oncologists are developing new treatment protocols. One such protocol, entitled dose-adjusted EPOCH-R, utilizes two major new strategies. First, the treatment approach utilizes continuous infusion of chemotherapy over four days, instead of being administered over minutes or hours. Secondly, the doses of some medications involved are increased or decreased based on how the drugs affect the subject's ability to produce blood cells, which is used as a measure of how rapidly the body is processing drugs. Using this approach in adults, researchers have shown improved cure rates in these cancers. Additionally, the harmful effects experienced by patients has been mild, with mucositis, severe infections, and tumor lysis syndrome occurring rarely. However, this new dosing method has never been used in children, and the effectiveness and side effects of this new method are unknown in children. The purpose of this study is to look at the safety of dose-adjusted EPOCH-R in the treatment of children with mature B-cell cancers, and to see if we can maintain cure rates (as has been shown in adults). This study represents the first trial of dose-adjusted EPOCH-R in children.
New Dosage	NCT01760226 ↗	Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies	Completed	Texas Children's Hospital	Early Phase 1	2013-01-01	The subject is invited to take part in this research study because s/he has been diagnosed with Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal B-cell Lymphoma (PMBCL), or Post-transplant Lymphoproliferative Disorder (PTLD). In an attempt to improve cure rates while reducing harmful effects from drugs, oncologists are developing new treatment protocols. One such protocol, entitled dose-adjusted EPOCH-R, utilizes two major new strategies. First, the treatment approach utilizes continuous infusion of chemotherapy over four days, instead of being administered over minutes or hours. Secondly, the doses of some medications involved are increased or decreased based on how the drugs affect the subject's ability to produce blood cells, which is used as a measure of how rapidly the body is processing drugs. Using this approach in adults, researchers have shown improved cure rates in these cancers. Additionally, the harmful effects experienced by patients has been mild, with mucositis, severe infections, and tumor lysis syndrome occurring rarely. However, this new dosing method has never been used in children, and the effectiveness and side effects of this new method are unknown in children. The purpose of this study is to look at the safety of dose-adjusted EPOCH-R in the treatment of children with mature B-cell cancers, and to see if we can maintain cure rates (as has been shown in adults). This study represents the first trial of dose-adjusted EPOCH-R in children.
New Dosage	NCT01760226 ↗	Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies	Completed	Baylor College of Medicine	Early Phase 1	2013-01-01	The subject is invited to take part in this research study because s/he has been diagnosed with Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal B-cell Lymphoma (PMBCL), or Post-transplant Lymphoproliferative Disorder (PTLD). In an attempt to improve cure rates while reducing harmful effects from drugs, oncologists are developing new treatment protocols. One such protocol, entitled dose-adjusted EPOCH-R, utilizes two major new strategies. First, the treatment approach utilizes continuous infusion of chemotherapy over four days, instead of being administered over minutes or hours. Secondly, the doses of some medications involved are increased or decreased based on how the drugs affect the subject's ability to produce blood cells, which is used as a measure of how rapidly the body is processing drugs. Using this approach in adults, researchers have shown improved cure rates in these cancers. Additionally, the harmful effects experienced by patients has been mild, with mucositis, severe infections, and tumor lysis syndrome occurring rarely. However, this new dosing method has never been used in children, and the effectiveness and side effects of this new method are unknown in children. The purpose of this study is to look at the safety of dose-adjusted EPOCH-R in the treatment of children with mature B-cell cancers, and to see if we can maintain cure rates (as has been shown in adults). This study represents the first trial of dose-adjusted EPOCH-R in children.
OTC	NCT03742258 ↗	Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma	Active, not recruiting	National Cancer Institute (NCI)	Phase 1	2019-03-13	The purpose of this research study is to evaluate a new investigational drug, TAK-659, given in combination with standard chemotherapy, for the treatment of Diffuse Large B-cell Lymphoma (DLBCL). ?Investigational? means that TAK-659 has not been approved by the United States Food and Drug Administration (FDA) for use as a prescription or over-the-counter medication to treat a certain condition. The primary purpose of this study is to find the appropriate and safe dose of the study drug to be used in combination with standard chemotherapy for the treatment of your disease and to determine how well the drug works in treating the disease. Other objectives include measuring the amount of the study drug in the body at different times after taking the study drug. Participation in the study is expected to last for up to 3 years after receiving the last dose of the study drug. Patients will receive the study treatment for up to 18 weeks, as long as they are benefitting.
OTC	NCT03742258 ↗	Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma	Active, not recruiting	Northwestern University	Phase 1	2019-03-13	The purpose of this research study is to evaluate a new investigational drug, TAK-659, given in combination with standard chemotherapy, for the treatment of Diffuse Large B-cell Lymphoma (DLBCL). ?Investigational? means that TAK-659 has not been approved by the United States Food and Drug Administration (FDA) for use as a prescription or over-the-counter medication to treat a certain condition. The primary purpose of this study is to find the appropriate and safe dose of the study drug to be used in combination with standard chemotherapy for the treatment of your disease and to determine how well the drug works in treating the disease. Other objectives include measuring the amount of the study drug in the body at different times after taking the study drug. Participation in the study is expected to last for up to 3 years after receiving the last dose of the study drug. Patients will receive the study treatment for up to 18 weeks, as long as they are benefitting.

All Clinical Trials for NEOSAR

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002524 ↗	Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma	Completed	National Cancer Institute (NCI)	Phase 2	1993-06-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with AIDS-related lymphoma.
NCT00002524 ↗	Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma	Completed	M.D. Anderson Cancer Center	Phase 2	1993-06-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with AIDS-related lymphoma.
NCT00002829 ↗	Bone Marrow Transplantation in Treating Patients With Lymphoma	Completed	National Cancer Institute (NCI)	Phase 2	1994-02-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells, and may be an effective treatment for lymphoma. Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill cancer cells. PURPOSE: Phase II trial to study the effectiveness of bone marrow transplantation in treating patients with recurrent or residual low-grade lymphoma.
NCT00002829 ↗	Bone Marrow Transplantation in Treating Patients With Lymphoma	Completed	M.D. Anderson Cancer Center	Phase 2	1994-02-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells, and may be an effective treatment for lymphoma. Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill cancer cells. PURPOSE: Phase II trial to study the effectiveness of bone marrow transplantation in treating patients with recurrent or residual low-grade lymphoma.
NCT00002831 ↗	Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia	Completed	National Cancer Institute (NCI)	Phase 1/Phase 2	1995-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of high-dose chemotherapy plus peripheral stem cell transplantation in treating patients with chronic myelogenous or acute leukemia.
NCT00002831 ↗	Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia	Completed	M.D. Anderson Cancer Center	Phase 1/Phase 2	1995-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of high-dose chemotherapy plus peripheral stem cell transplantation in treating patients with chronic myelogenous or acute leukemia.

Clinical Trial Conditions for NEOSAR

Condition Name

Condition Name for NEOSAR
Intervention	Trials
Acute Lymphoblastic Leukemia	47
Leukemia	45
Lymphoma	40
Myelodysplastic Syndrome	24

Condition MeSH

Condition MeSH for NEOSAR
Intervention	Trials
Lymphoma	147
Leukemia	147
Leukemia, Lymphoid	114
Precursor Cell Lymphoblastic Leukemia-Lymphoma	94

Clinical Trial Locations for NEOSAR

Trials by Country

Trials by Country for NEOSAR
Location	Trials
New Zealand	44
Brazil	9
Switzerland	9
Ireland	9
Italy	8

Trials by US State

Trials by US State for NEOSAR
Location	Trials
Texas	196
California	134
Washington	105
New York	96
Pennsylvania	91

Clinical Trial Progress for NEOSAR

Clinical Trial Phase

Clinical Trial Phase for NEOSAR
Clinical Trial Phase	Trials
Phase 3	61
Phase 2/Phase 3	3
Phase 2	172

Clinical Trial Status

Clinical Trial Status for NEOSAR
Clinical Trial Phase	Trials
Recruiting	118
Completed	114
Active, not recruiting	85

Clinical Trial Sponsors for NEOSAR

Sponsor Name

Sponsor Name for NEOSAR
Sponsor	Trials
National Cancer Institute (NCI)	268
M.D. Anderson Cancer Center	122
Fred Hutchinson Cancer Research Center	33

Sponsor Type

Sponsor Type for NEOSAR
Sponsor	Trials
Other	436
NIH	287
Industry	142

Neosar Clinical Trials, Market Analysis, Patent Status and 2030 Projection

Last updated: July 31, 2026

Neosar is a cyclophosphamide formulation used as an alkylating chemotherapy agent and immunosuppressant. Its commercial outlook is driven by the broader cyclophosphamide injectable market, not by a standalone Neosar franchise. Cyclophosphamide has extensive clinical evidence, no meaningful remaining originator exclusivity, and competition from multiple generic injectable suppliers. Growth is likely to remain modest through 2030, with demand tied to oncology treatment volumes, autoimmune disease use, supply reliability and hospital procurement pricing.

What is Neosar and what active ingredient does it contain?

Neosar is a prescription product containing cyclophosphamide for injection. Cyclophosphamide is a nitrogen-mustard alkylating agent that inhibits DNA replication and cell division. It is used in oncology regimens and, at different doses, for severe immune-mediated diseases.

Attribute	Neosar
Active ingredient	Cyclophosphamide
Drug class	Alkylating antineoplastic agent; immunosuppressant
Main dosage form	Powder for solution for intravenous injection
Common strengths	500 mg, 1 g and 2 g presentations, depending on supplier and market
Main clinical uses	Lymphomas, leukemias, breast cancer, ovarian cancer, multiple myeloma and other malignancies
Immunology uses	Severe lupus, vasculitis and other refractory autoimmune conditions
FDA regulatory category	Prescription generic drug product
Administration	Intravenous; oral cyclophosphamide products also exist in some markets
Key safety risks	Myelosuppression, hemorrhagic cystitis, infertility, secondary malignancies, cardiotoxicity and immunosuppression

Neosar is not a novel molecular entity. It is one branded or supplier-specific presentation of a long-established active pharmaceutical ingredient. FDA labeling identifies cyclophosphamide’s use across several malignancies and describes hydration, urinary monitoring and mesna use as clinically appropriate to reduce urotoxicity risk [1].

What is the FDA status of Neosar?

Neosar is regulated as a conventional small-molecule drug, not as a biologic. Its regulatory value is therefore different from products that depend on biologic reference-product exclusivity or biosimilar barriers.

The FDA-approved cyclophosphamide label includes dosing information for combination chemotherapy and single-agent treatment. Treatment protocols vary substantially by indication, disease stage, patient age, renal function, hepatic function and combination regimen.

The FDA’s regulatory framework permits abbreviated new drug applications for therapeutically equivalent cyclophosphamide products. Generic competitors do not need to repeat the full clinical development program that supported the original cyclophosphamide approvals. They must demonstrate pharmaceutical equivalence, bioequivalence where applicable, manufacturing quality and compliance with FDA requirements.

Is Neosar still a novel clinical development product?

No. Neosar is a mature commercial product. Clinical research continues on cyclophosphamide-containing regimens, but those trials generally evaluate the active ingredient in a new combination, indication, dose intensity or treatment sequence. The trials do not represent clinical development of Neosar as a new drug.

What clinical trials are evaluating cyclophosphamide?

Cyclophosphamide remains active in clinical research because it is used as a backbone or conditioning component in several therapeutic settings.

Oncology trials

Current and recent research areas include:

• Combination treatment for aggressive lymphomas and leukemias.
• Conditioning regimens before hematopoietic stem-cell transplantation.
• Combination therapy with monoclonal antibodies, antibody-drug conjugates and cellular therapies.
• Dose-intensified chemotherapy in selected breast and hematologic cancers.
• Immunomodulatory combinations in solid tumors.
• Lymphodepletion before adoptive cell therapy.

Cyclophosphamide is often included in multi-agent protocols such as CHOP-like regimens, high-dose conditioning programs and lymphodepletion protocols. In these studies, the investigational question usually concerns the companion drug or treatment strategy rather than cyclophosphamide itself.

Autoimmune and immune-mediated disease trials

Cyclophosphamide continues to be studied or used for severe disease that has failed safer therapies. Relevant areas include:

• ANCA-associated vasculitis.
• Severe lupus nephritis.
• Systemic sclerosis with serious organ involvement.
• Refractory inflammatory neurologic disease.
• Immune-mediated pulmonary and renal disorders.
• Severe autoimmune disease requiring rapid immunosuppression.

Use in these diseases is limited by cumulative toxicity. Treatment has increasingly shifted toward rituximab, mycophenolate, belimumab, voclosporin and other targeted or less toxic options where clinically appropriate [2].

What is the clinical evidence supporting cyclophosphamide?

Cyclophosphamide’s evidence base is extensive, but it is distributed across decades of studies rather than a single modern registration trial. Strong evidence exists for its role in combination chemotherapy and induction treatment for severe autoimmune disease. The main clinical limitation is its toxicity profile, which constrains duration and cumulative exposure.

The most important safety issues are:

• Bone-marrow suppression and infection.
• Hemorrhagic cystitis and bladder toxicity.
• Gonadal failure and infertility.
• Treatment-related leukemia and other secondary cancers.
• Cardiac and pulmonary toxicity at high doses.
• Teratogenicity and fetal harm.

The National Cancer Institute and FDA continue to identify cyclophosphamide as an established cytotoxic agent with broad oncology use [1, 3].

What patents protect Neosar and cyclophosphamide?

No material composition-of-matter patent protection remains for cyclophosphamide. The molecule was introduced decades ago, and the originator patent estate has expired.

Patent category	Current relevance to Neosar
Cyclophosphamide composition patent	Expired
Original oncology method patents	Expired or commercially immaterial
Basic injectable formulation patents	Expired or unavailable as a meaningful barrier
Manufacturing patents	Potentially relevant to individual suppliers but generally non-blocking
New combination patents	May protect specific regimens, not Neosar itself
New use patents	May apply to a defined disease, dose or treatment population
Device or packaging patents	Could apply to a supplier presentation but do not protect the active ingredient

The commercial barriers for cyclophosphamide are manufacturing quality, sterile production capacity, regulatory compliance, supply continuity and hospital contracting. Patent exclusivity is not the primary barrier.

How strong is the Neosar patent estate?

The Neosar patent estate is weak from an exclusivity perspective because the product depends on an old small-molecule active ingredient. Any remaining rights would more likely concern a specific formulation, manufacturing process, container closure or later-developed treatment method.

Those rights would not ordinarily prevent generic suppliers from marketing standard cyclophosphamide injection if they can demonstrate compliance with applicable FDA requirements.

When does Neosar lose exclusivity?

Neosar’s core exclusivity has already expired. Cyclophosphamide is a genericized active ingredient with multiple suppliers and no expected new chemical entity exclusivity.

The relevant commercial timeline is therefore:

Milestone	Timing
Original cyclophosphamide development and approval	Historical, mid-20th century
Originator patent protection	Expired
Generic injectable competition	Established
Neosar-specific exclusivity	No meaningful current exclusivity
Expected generic entry risk	Already present
Near-term exclusivity event	None identified for the core product

Any market protection would need to arise from a new formulation, delivery system, combination, indication or manufacturing innovation. Standard Neosar injection does not have that profile.

What is the Orange Book status of Neosar?

The FDA Orange Book lists approved drug products and patent information for products subject to applicable listing requirements. Cyclophosphamide injectable products are generally assessed as conventional generic products rather than as protected branded innovations.

Orange Book implications include:

• The product category is subject to abbreviated approval pathways.
• Multiple cyclophosphamide products may be listed by different manufacturers.
• Therapeutic-equivalence evaluations depend on the specific dosage form and strength.
• Patent listings, where present, would need to be reviewed at the individual product level.
• A product’s presence in the Orange Book does not establish current commercial availability.

Neosar should not be analyzed like a patent-protected branded oncology product such as a recently approved targeted therapy. The relevant competitive question is whether approved suppliers can maintain reliable sterile injectable supply.

Which companies compete with Neosar?

Competition comes from suppliers of cyclophosphamide for injection rather than from a single direct branded rival. Depending on market and presentation, competitors may include generic injectable manufacturers such as Hikma, Fresenius Kabi, Pfizer-associated legacy products, Baxter, Sagent, Teva and other FDA-approved or regionally approved suppliers.

The competitive set changes by:

• Strength and vial size.
• Ready-to-use versus powder presentation.
• Preservative status.
• Hospital contract awards.
• Shortage conditions.
• National tender systems.
• Availability of pharmacy bulk packages.
• Supplier manufacturing capacity.

The principal commercial competitors are not differentiated by clinical efficacy. They compete on price, quality record, supply reliability, packaging and procurement terms.

What generic entry risks exist for Neosar?

Generic entry is not a future risk for Neosar. It is the existing market structure.

The main risks to a Neosar-branded or supplier-specific product are:

1. Price erosion from interchangeable injectable products.
2. Hospital conversion to lower-cost contract suppliers.
3. Loss of formulary preference.
4. Supplier substitution during shortages.
5. Tender-driven procurement in public healthcare systems.
6. Reduced use in autoimmune disease as targeted immunotherapies expand.
7. Clinical movement toward less toxic chemotherapy combinations.

The main countervailing factor is that sterile injectable production is operationally difficult. A nominally competitive market can experience supply shortages when one or more manufacturers encounter contamination events, manufacturing delays, raw-material constraints or regulatory action.

How large is the cyclophosphamide market?

Public market reports often combine cyclophosphamide injection, oral products and multiple geographic markets. They also use different definitions of market revenue. Reported estimates therefore vary materially and should not be treated as directly comparable.

A more defensible commercial assessment is:

Market driver	Direction through 2030	Effect on Neosar
Global cancer incidence	Positive	Supports baseline demand
Hematologic cancer treatment	Positive	Supports injectable use
Stem-cell transplantation and cellular therapy	Positive in selected centers	Supports conditioning and lymphodepletion
Autoimmune use	Mixed	Demand persists, but alternatives displace some use
Generic price competition	Negative	Reduces revenue per unit
Sterile injectable shortages	Volatile	Can increase short-term prices and share shifts
Hospital purchasing concentration	Negative	Compresses supplier margins
New targeted oncology therapies	Mixed	Reduces some chemotherapy use but creates combination demand

The market is likely to expand in units at a low single-digit rate in a base case, while revenue growth remains lower because of generic price erosion. A high-growth scenario would require sustained oncology volume growth, increased conditioning use or recurring injectable shortages. A downside scenario would involve accelerated substitution by targeted therapies and greater procurement pressure.

What is the 2030 market projection for Neosar?

Because Neosar is not consistently reported as a separate commercial segment, the following projection applies to the cyclophosphamide injectable opportunity rather than a verified Neosar-only revenue figure.

Scenario	Unit demand, 2024-2030	Revenue trend, 2024-2030	Main assumptions
Downside	Flat to 1% annual growth	Decline of 2% to 5% annually	Strong price erosion and substitution
Base case	2% to 4% annual growth	Flat to 2% annual growth	Oncology growth offsets generic pricing
Upside	4% to 6% annual growth	2% to 5% annual growth	Higher transplant, cellular therapy and shortage demand

The base case is the most credible commercial scenario. Cyclophosphamide is inexpensive, clinically established and difficult to replace completely in several chemotherapy and conditioning protocols. Revenue growth should remain constrained because the product has no meaningful patent protection and buyers can switch suppliers.

What manufacturing and intellectual-property barriers affect Neosar?

The principal barriers are manufacturing and regulatory rather than intellectual property.

Sterile manufacturing

Cyclophosphamide injection requires validated sterile processing, container-closure integrity, environmental control and quality testing. Manufacturing failures can trigger recalls, supply interruptions or FDA enforcement action.

Occupational handling controls

Cyclophosphamide is hazardous to healthcare workers. Suppliers must support appropriate handling, labeling and packaging requirements. Hospitals may favor products that simplify reconstitution, reduce exposure risk or improve pharmacy workflow.

Supply-chain resilience

API sourcing, sterile fill-finish capacity and vial availability affect market share. In a shortage, a supplier with available inventory may gain temporary volume even without a superior product.

Formulation and packaging opportunities

Potential differentiation areas include:

• Ready-to-use liquid formulations.
• Reduced-reconstitution systems.
• Closed-system transfer compatibility.
• Lower exposure packaging.
• Extended stability after reconstitution.
• Smaller or larger vial configurations.
• Improved cold-chain or room-temperature handling.

These improvements could support new patent or regulatory filings, but they would protect a specific presentation rather than cyclophosphamide as a molecule.

What licensing deals affect Neosar?

No major current licensing transaction is required to commercialize standard cyclophosphamide injection. The product is a mature generic medicine, and licensing economics generally concern:

• Distribution rights.
• Regional marketing authorization transfer.
• Contract manufacturing.
• Hospital tender supply.
• API or fill-finish agreements.
• Portfolio acquisitions involving generic injectables.

Any licensing deal should be evaluated for manufacturing dependence, minimum purchase obligations, supply guarantees, change-of-control provisions and liability allocation. The commercial value of a Neosar-related deal would depend more on supply access and geographic rights than on patent assets.

What patent litigation or Paragraph IV challenges affect Neosar?

No significant current patent litigation is expected to define the standard cyclophosphamide injection market. Paragraph IV litigation is primarily relevant when an ANDA applicant challenges an unexpired listed patent. Because core cyclophosphamide protection has expired, the probability of a commercially important Paragraph IV event involving the basic product is low.

Potential disputes could still involve:

• A newly listed formulation patent.
• A specific container or delivery system.
• A narrow method-of-use claim.
• Manufacturing-process rights.
• Contract or regulatory exclusivity disputes.

These would be product-specific and would not restore broad protection for Neosar.

How does Neosar compare with newer oncology drugs?

Factor	Neosar/cyclophosphamide	New targeted oncology drug
Molecular protection	Expired	Often active
Price	Low generic price	Frequently high branded price
Clinical role	Backbone, combination or conditioning agent	Biomarker- or pathway-directed treatment
Evidence base	Decades of clinical use	Recent registration studies
Supplier competition	High	Often limited initially
Margin profile	Low	Higher during exclusivity
Supply risk	Sterile manufacturing dependent	API, biologic or specialty manufacturing dependent
Main commercial risk	Price erosion and procurement	Patent challenge and clinical displacement

Key Takeaways

• Neosar is a cyclophosphamide injection product, not a novel drug.
• Its core patent and regulatory exclusivity have expired.
• Clinical trials continue to study cyclophosphamide-containing regimens, especially in oncology, transplantation, cellular therapy and severe autoimmune disease.
• The product competes primarily through generic injectable supply, pricing, quality and availability.
• Patent litigation and Paragraph IV risk are low for the standard molecule.
• Manufacturing reliability is more important than intellectual property.
• Injectable demand should grow modestly through 2030, but generic pricing will limit revenue growth.
• Targeted oncology medicines will displace some uses while preserving cyclophosphamide demand in combination regimens and conditioning protocols.
• A new formulation or delivery system could create differentiated value, but standard Neosar has limited strategic exclusivity.

FAQs

Is Neosar the same as Cytoxan?

Neosar and Cytoxan contain the same active ingredient, cyclophosphamide. They may differ by manufacturer, formulation, packaging, labeling and market availability.

Is cyclophosphamide still used in cancer treatment?

Yes. It remains part of numerous chemotherapy combinations, lymphoma protocols, leukemia regimens, conditioning programs and cellular-therapy lymphodepletion protocols.

Can cyclophosphamide be replaced by rituximab?

Not universally. Rituximab can replace cyclophosphamide in some autoimmune treatment strategies, but the drugs have different mechanisms and are not interchangeable across oncology protocols.

Does Neosar have biosimilar competition?

No. Neosar is a small-molecule drug, so its competitors are generic cyclophosphamide products, not biosimilars.

What would create new commercial value for cyclophosphamide?

Commercial value could come from ready-to-use presentations, safer handling systems, improved stability, reliable shortage-resistant supply, differentiated packaging or a patented use in a defined treatment regimen.

References

1. U.S. Food and Drug Administration. (2023). Cyclophosphamide injection prescribing information. FDA/DailyMed.

2. Kidney Disease: Improving Global Outcomes. (2024). KDIGO 2024 clinical practice guideline for the evaluation and management of lupus nephritis. Kidney International.

3. National Cancer Institute. (2024). Cyclophosphamide. National Institutes of Health.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

5. ClinicalTrials.gov. (2024). Search results for cyclophosphamide interventional clinical studies. U.S. National Library of Medicine.